Hemispherx BioPharma Inc.

1.80-0.0100-0.55%Vol 14.90K1Y Perf -84.85%
Aug 30th, 2019 19:35 DELAYED
BID0.00 ASK0.00
Open1.97 Previous Close1.81
Pre-Market- After-Market-
 - -%  - -%
Target Price
8.00 
Analyst Rating
— — 0.00
Potential %
- 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
-/-/- 
Value Ranking
 —    -
Insiders Value % 3/6/12 mo.
-/-/- 
Growth Ranking
★★ —    -
Insiders Shares Cnt. % 3/6/12 mo.
-/-/- 
Income Ranking
 —    -
Market Cap4.40M 
Earnings Rating
Buy
Price Range Ratio 52W %
0.00 
Earnings Date
21st Aug 2019

Today's Price Range

1.781.97

52W Range

1.6914.81

Summary:

Technical Indicators:
Moving Averages:
Performance
1 Week
-
1 Month
-
3 Months
-
6 Months
-
1 Year
-84.85%
3 Years
-91.98%
5 Years
-98.30%
10 Years
-99.26%

TickerPriceChg.Chg.%
HEB1.80-0.0100-0.55
AAPL377.954.10001.10
GOOG1 511.5015.80001.06
MSFT213.132.43001.15
XOM43.73-0.6600-1.49
WFC24.72-0.7700-3.02
JNJ143.240.26000.18
FB247.186.90002.87
GE6.80-0.2000-2.86
JPM92.57-2.4300-2.56
Earnings HistoryEstimateReportedSurprise %
Q04 2016--0.04-
Q02 2016--0.01-
Q01 2016--0.01-
Q04 2015--0.01-
Q03 2015--0.02-
Q02 2015--0.02-
Q01 2015--0.02-
Q04 2014--0.02-
Earnings Per EndEstimateRevision %Trend
----
----
----
----
Next Report Date-
Estimated EPS Next Report-
Estimates Count-
EPS Growth Next 5 Years %-
Volume Overview
Volume14.90K
Shares Outstanding2.44M
Trades Count425
Dollar Volume345.50K
Avg. Volume102.60K
Avg. Weekly Volume23.82K
Avg. Monthly Volume111.79K
Avg. Quarterly Volume166.85K

Hemispherx BioPharma Inc. (AMEX: HEB) stock closed at 1.8 per share at the end of the most recent trading day (a -0.55% change compared to the prior day closing price) with a volume of 14.90K shares and market capitalization of 4.40M. Is a component of indices and it is traded on AMEX exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs people. Hemispherx BioPharma Inc. CEO is Thomas K. Equels.

The one-year performance of Hemispherx BioPharma Inc. stock is -84.85%, while year-to-date (YTD) performance is 0%. HEB stock has a five-year performance of -98.3%. Its 52-week range is between 1.69 and 14.81, which gives HEB stock a 52-week price range ratio of %

Hemispherx BioPharma Inc. currently has a PE ratio of -, a price-to-book (PB) ratio of -, a price-to-sale (PS) ratio of -, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -%, a ROC of -% and a ROE of -%. The company’s profit margin is -%, its EBITDA margin is -%, and its revenue ttm is $0.00 , which makes it $- revenue per share.

Of the last four earnings reports from Hemispherx BioPharma Inc., there were 0 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $0.00 for the next earnings report. Hemispherx BioPharma Inc.’s next earnings report date is -.

The consensus rating of Wall Street analysts for Hemispherx BioPharma Inc. is (), with a target price of $, which is 0.00% compared to the current price. The earnings rating for Hemispherx BioPharma Inc. stock is (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Hemispherx BioPharma Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Hemispherx BioPharma Inc. has a technical analysis rating based on Technical Indicators (), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Hemispherx BioPharma Inc. in the last 12-months were:

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
0 (0.00 %)
1 (100.00 %)
0
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0
Hold
1 (100.00 %)
0 (0.00 %)
0
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0
Strong Sell
0 (0.00 %)
0 (0.00 %)
0
Summary Rating---

Hemispherx BioPharma Inc.

Hemispherx Biopharma Inc is a US-based specialty pharmaceutical company. It is engaged in the clinical development of drug therapies based on natural immune system enhancing technologies for the treatment of viral and immune-based disorders. The products of the firm are Alferon N Injection and the experimental therapeutic Ampligen. Alferon N Injection is approved for a category of STD infection, and Ampligen represents a RNA being developed for viral diseases and disorders of the immune system. The sales revenue of the company is derived from the United States.

CEO: Thomas K. Equels

Teplephone: +1 215 988-0080

Address: 2117 SW Highway 484, Ocala 34473, FL, USA

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

100%0%

Bearish Bullish

50%50%

Bearish Bullish

67%33%

Bearish Bullish

65%35%

News

Stocktwits